Changelog
08/2023 - Updates
3 new substrates: abrocitinib active moiety, asciminib, netupitant.
3 new interactors: abrocitinib, asciminib, netupitant.
1 update of parameter values: ondansetron.
6 new references in the database.
11/2022 - Updates
12 new substrates: acalabrutinib, dapoxetine, dexamethasone, elexacaftor, finerenone, lemborexant, pemigatinib, selpercatinib, selumetinib, tezacaftor, upadacitinib, tucatinib.
7 new interactors: berotralstat, cenobamate, dapoxetine, tecovirimat, tucatinib.
18 new references in the database.
02/2022 - Updates
11 new substrates: avapritinib, fedratinib, fostemsavir, lonafarnib, nirmatrelvir/r, perampanel, pexidartinib, quizartinib, rimegepant, ubrogepant, voclosporin.
5 new interactors: fedratinib, lonafarnib, pexidartinib, viloxazine, voclosporin.
WARNING 5 updates of parameter values: ruxolitinib, cimetidine, quinine, ciprofloxacin, erlotinib.
19 new references in the database.
06/2021 - Updates
7 new substrates: bromazepam, clindamycin, darolutamide, drospirenone, etravirin, gilteritinib, panobinostat.
4 new interactors: darolutamide, fosamprenvir/r, tipranavir/r, panobinostat.
WARNING 3 updates: the inhibition ratio of low dose ritonavir for CYP2D6 has been revised (reduced). This modification holds also for combinations of ritonavir with darunavir and lopinavir.
41 new references in the database.
09/2020 - Updates
16 new substrates: avanafil, brigatinib, ceritinib, dacomitinib, doravirine, dronabinol, encorafenib, erdafitinib, esaxerenone, laquinimod, lorlatinib, naldemedine, neratinib, suvorexant, yohimbine, zanubrutinib.
2 new inhibitors: cilostazole, dacomitinib.
5 new inducers: apalutamide, ceritinib, dicloxacillin, lorlatinib, zanubrutinib.
WARNING 4 updates: the AUC ratio for prodrugs (clopidogrel, codeine, proguanil, tamoxifen) is now expressed in terms of the active metabolite. Hence, if the AUC ratio is less than 1, the dose should be increased.
57 new references in the database.
12/2019 – Updates
7 new substrates: carbamazepine, etizolam, lomitapide, netupitant, palonosetron, siponimod, zafirlukast
2 new inhibitors: lomitapide, nitisinone
3 updates: buprenorphine, cinacalcet, propranolol
53 new references in the references database.
04/2019 - Updates
Hundred drugs which are NOT at risk of interaction with cytochrome inhibitors have been added to the list of substrates.
4 new substrates: abemaciclib, esomeprazole, mizolastine, ribociclib.
4 new inhibitors: darifenacin, esomeprazole, ribociclib, rucaparib.
1 update: clopidogrel (CR).
35 new references in the references database.
10/2018 - Updates
5 new substrates: antipyrine, apatinib, hydrocodone, ramosetron and tofacitinib
2 new inhibitors: ecstasy and letermivir
4 new inducers: bosentan, letermovir, mitotane, rifampicin 1200 mg/d
6 updates: mianserin (CR), olanzapine (CR), quinine (CR), carbamazepine (IX), rifabutin (IX) and nicardipine (IX)
75 new references in the references database.
03/2018 - Updates
1 new publication A new article entitled "Identification of CYP-mediated DDIs at risk in case of gene polymorphism" is published in Clinical Pharmacokinetics. A redlist of the cases at risk has been added (see the tab Tool/DDIs at risk).
6 new substrates: brexpiprazole, cariprazine, flibanserin, lidocaine, maprotiline, palbociclib
9 new inhibitors: armodafinil, asunaprevir, ivabradine, josamycin, lesinurad, palbociclib, panobinostat, rolapitant, simeprevir
1 update: fluvoxamine (cyp2D6 inhibition)
3 new inducers: armodafinil, lesinurad, lumacaftor
39 new references in the references database.
10/2017 - Version 3.1
Effect of age on the magnitude of DDIs added Tolerance interval of the AUC ratios added 1 substrate update: Mirtazapine, Propranolol
07/2017 – Updates
1 inhibitor update: pazopanib 2 new inducers: rufinamide, teriflunomide 7 new substrates: fesoterodine, naloxegol, pirfenidone, pitolisant, tolvaptan, ulipristal, vilazodone 14 new references
02/2017 - Updates
4 new Inhibitors: Escitalopram, Clobazam, Isavuconazole, Lurasidone 10 new Substrates: Disopyramide, Loratadine, Isavuconazole, Ondansetron, Estradiol valerate, Dienogest, Fostamatinib, Gemigliptin, Lurasidone, Vortioxetine 27 new references
11/2016 - Updates
4 new substrates: Bortezomib, Cobimetinib, Cabozantinib, Ponatinib 2 updates: Dabrafenib, Pomalidomide
04/2016 - Updates
Two new papers on DDI-Predictor (see publications tab). In the Int J Pharmacokinet paper, a large validation on 628 cases and a comparison with Simcyp on 104 cases of DDI.
04/2016 - Updates
15 new substrates: Alisporivir, Amlodipine, Apremilast, Buprenorphine, Casopitant, Domperidone, Eletriptan, Ivabradine, Ivacaftor, Olaparib, Pimozide, Ranolazine, Silodosin, Tamsulosin, Tamiselteon 2 new inhibitors: Bicalutamide, Casopitant
2 new inducers: Modafinil, Pentobarbital 1 update: Tolterodine
09/2015 - Updates
9 new substrates: Aprepitant, Cinacalcet, Dexamethasone, Ethinyl estradiol, Ibrutinib, Mirabegron, Trazodone, Vandetanib, Vardenafil 7 new inhibitors: Amlodipine, Aprepitant, Cinacalcet, Hydroxychloroquine, Idelalisib, Mirabegron, Nicardipine
4 new inducers: Aprepitant, Esclicarbazepine, Oxcarbazepine, Phenobarbital 3 updates: Ketoconazole, Imipramine, Ramelteon
04/2015 - Version 2.0
Drug list extended. CYP1A2 added. Cirrhosis and DDIs in cirhosis added. Validation suite and references added.
03/2013 - Version 1.0
First launch.